Veterans Health Administration will cover Alzheimer's treatment Leqembi, Eisai says
Publishing timestamp: 2023-03-13 18:40:54
Summary
Veterans Health Administration will cover Eisai and Biogen's Alzheimer's treatment Leqembi for veterans with early Alzheimer's who meet certain VHA criteria. Medicare is not covering the treatment except in very limited circumstances, making it out of reach for the majority of seniors. Leqembi slowed cognitive decline in people with early Alzheimer's by 27% in late-stage trial, but also carries risks of brain swelling and bleeding. Medicare has agreed to provide broader coverage of Leqembi as soon as it receives full approval from FDA, which is expected in July.
Sentiment: NEUTRAL
Tickers: ESALY, 4523.T-JP, BIIB,
Keywords: health care industry, business, eisai co ltd, pharmaceuticals, biogen inc, breaking news: business, veterans healthcare, business news, u.s. economy, biotech and pharmaceuticals, alzheimer's disease, veterans,